ABSTRACT
Acyclic nucleosides differ from conventional nucleosides in that the sugar ring is replaced by an acyclic moiety. The first acyclic nucleoside to show selective inhibition of HSV replication was acyclovir (1.47, Zovirax®, ACV)>1,2 a guanosine based nucleoside whose clinical effectiveness3 has stimulated considerable interest in acyclic nucleosides (Fig. 8.1).
